Fecal microbiota, sold under the brand name, Rebyota is used for the prevention of recurrence of Clostridioides difficile infection.
[4] Fecal microbiota is approved for the prevention of recurrence of Clostridioides difficile infection (CDI) in people 18 years of age and older.
[4] They received one or more doses of fecal microbiota or placebo 24 to 72 hours after completion of antibiotic treatment for their Clostridioides difficile infection; participants' Clostridioides difficile infection was under control at the time of receipt of fecal microbiota or placebo.
[4] In one study, among 180 fecal microbiota recipients, when compared to 87 placebo recipients, the most common side effects after receiving one dose of fecal microbiota were abdominal pain, diarrhea, abdominal bloating, gas and nausea.
[4] The FDA granted the application for fecal microbiota, live fast track, breakthrough therapy, and orphan drug designations.